Edition:
United Kingdom

Bionano Genomics Inc (BNGO.OQ)

BNGO.OQ on NASDAQ Stock Exchange Capital Market

6.95USD
17 Oct 2018
Change (% chg)

$0.20 (+2.96%)
Prev Close
$6.75
Open
$6.99
Day's High
$6.99
Day's Low
$6.61
Volume
1,565
Avg. Vol
--
52-wk High
$10.00
52-wk Low
$6.00

Summary

Name Age Since Current Position

David Barker

73 Chairman of the Board

Erik Holmlin

48 President, Chief Executive Officer, Director

Han Cao

2016 Founder, Chief Scientific Officer

Sean Paolino

Vice President - Finance

Mike Ward

Vice President - Corporate Development

Biographies

Name Description

David Barker

Dr. David L. Barker is the Chairman of the Board of the Company. David L. Barker currently serves on the board of directors at Bionano Genomics and AmideBio and is a board member and chairman at Integrated Diagnostics and IntegenX, Inc. Dr. Barker is a scientific advisor to MiNDERA Corp. and Illumina, Inc., where he was vice president and chief scientific officer from 2000 to 2007. He was previously on the boards of NextBio, which was acquired by Illumina in 2013; ProteinSimple, which was acquired by Bio-Techne in 2014; and Zephyrus Biosciences, Inc., which was acquired by Bio-Techne in 2016. Dr. Barker served, from 1998 to 2000, as vice president and chief science advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including vice president of research and business development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham. In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School and was an assistant professor at the University of Oregon and an associate professor at Oregon State University. Dr. Barker holds a bachelor’s degree, with honors, in chemistry from the California Institute of Technology and a PhD in biochemistry from Brandeis University.

Erik Holmlin

Dr. Erik Holmlin is President, Chief Executive Officer, Director of BioNano Genomics, Inc. Erik Holmlin is a dynamic leader with more than two decades of experience developing innovative solutions and companies in the life sciences and healthcare industries. Erik’s experience includes positions at GenVault Corporation (CEO), Exiqon A/S (CCO) and Becton Dickinson (vice president of marketing and development). In 2001, Erik led the formation and financing efforts of GeneOhm Sciences, Inc. and orchestrated the company’s acquisition by Becton Dickinson in 2006. He also served as an entrepreneur in residence (EIR) at leading life-science venture capital firm Domain Associates, LLC. Erik was a National Institutes of Health postdoctoral fellow at Harvard University and a National Science Foundation predoctoral fellow at the California Institute of Technology, Pasadena (Caltech). He holds a PhD in chemistry from Caltech and MBAs from UC Berkeley and Columbia University.

Han Cao

Dr. Han Cao is Founder and Chief Scientific Officer of BioNano Genomics, Inc. Han Cao founded Bionano Genomics in 2003 as a spinoff of the Princeton University laboratories, where he was working on a multimillion-dollar project funded by the U.S. Defense Advanced Research Projects Agency (DARPA). Dr. Cao is the key co-inventor of the company’s core single-molecule nanoscale whole genome analysis technology. Prior to that, he was a postdoctoral fellow working on a stem cell and DNA repair system at the Institute for Human Gene Therapy of University of Pennsylvania Medical Center. His diverse experience includes molecular biology, microarray and genomics technology development, and single-molecule analysis, as well as micro and nanofluidics design and fabrication. Dr. Cao leads multiple federal government-funded projects at Bionano and has served on many grant review panels. He oversees the scientific and technical direction of future technology and product development at Bionano. Dr. Cao received his bachelor’s degree from the University of Science and Technology of China and his PhD in molecular biology from the University of Delaware.

Sean Paolino

Mr. Sean Paolino is the Vice President - Finance of the Company. Sean Paolino is an experienced financial leader with over 20 years of financial planning and analysis and accounting experience across multiple industries, including life sciences, consumer products, technology and chemicals. Most recently, Sean supported a portfolio of companies in the diagnostic, medical device and technology sectors after serving as the senior director of finance at Road Runner Sports. Prior to these roles, he spent three years at Life Technologies, helping to lead the North American FP&A team for a $1.4 billion business and supporting the integration of Invitrogen and Applied Biosystems. Sean began his career with PepsiCo/Pepsi Bottling Group and spent 15 years there, eventually helping to lead a billion-dollar business unit to the highest economic performance. He holds a bachelor’s degree in business administration and accounting from California State University, Fullerton.

Mike Ward

Mr. Mike Ward serves as Vice President - Corporate Development of the Company. Mike Ward has more than 20 years of experience in life sciences-dedicated investment banking, venture capital and private equity investments. Before joining Bionano Genomics, Mike was at Lurie Investment Fund, where he was responsible for managing the life sciences venture capital and private equity investments of the Lurie family. Mike guided senior management teams of Lurie’s life sciences portfolio companies in conducting business and corporate development, clinical and regulatory strategy, commercialization planning, intellectual property management, M&A, and financings. During his tenure, Mike also served on the boards of a number of life sciences portfolio companies on behalf of Lurie. Prior to joining Lurie Investment Fund, Mike gained more than 15 years of investment banking experience at Leerink Partners, Credit Suisse, Dresdner Kleinwort Wasserstein, BMO and Vector Securities. During his career in investment banking, Mike executed more than 80 life sciences mergers, acquisitions, divestitures, strategic alliances, private placements, IPOs and follow-on public offerings. In his more than two decades of experience serving and fostering life sciences companies, Mike has focused predominantly on the medical technology, tools, diagnostics and biopharmaceutical markets. Mike received, with summa cum laude distinction, a bachelor’s in finance from the University of Illinois.

Basic Compensation

Name Fiscal Year Total

David Barker

--

Erik Holmlin

--

Han Cao

--

Sean Paolino

--

Mike Ward

--
As Of 

Options Compensation